BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, released a Chairman's update on June 30, 2026, highlighting sales growth, strategic progress, and a return to profitability. Chairman Richard Staelin, PhD, detailed the company's focus on expanding revenues and markets while maintaining disciplined cost control.
The company reported a small profit for calendar year 2025, driven by cost-cutting measures that included relocating offices and reducing staff. These efforts allowed BioElectronics to align operations with current needs while investing in initiatives to increase awareness and adoption of its technology platforms.
A key revenue-generating initiative involves targeted advertising campaigns directed at medical professionals and healthcare providers. These campaigns aim to expand clinical awareness of RecoveryRx among surgeons, pain specialists, rehabilitation providers, and chiropractors seeking non-opioid pain management options. Additionally, the company has expanded consumer-focused social media advertising targeting Generation X consumers to boost brand visibility for drug-free chronic musculoskeletal pain solutions.
BioElectronics continues outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx. The goal is to participate in a postoperative clinical study that may support future qualification for reimbursement under the federal NO PAIN Act initiative, which could drive broader adoption of non-opioid pain management technologies in surgical settings.
Internationally, the company is working with legal counsel in Singapore and funders in China regarding arbitration proceedings involving a former distributor believed to have breached contractual obligations. While arbitration processes are lengthy, BioElectronics remains committed to protecting its intellectual property and shareholder interests.
A significant milestone is the strategic distribution and licensing relationship with Electrome Corporation. Initial conditions for the supply agreement have been satisfied, with BioElectronics receiving Electrome's initial purchase order. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products through its platform. This partnership provides another pathway to increase consumer awareness and access to FDA-cleared, drug-free pain therapy products.
Despite challenges faced by emerging medical technology companies, Staelin expressed encouragement over growing interest in non-drug pain management solutions and the long-term potential of BioElectronics' technology platforms. The company believes it is well positioned within the evolving electroceutical and non-opioid pain management markets and intends to continue advancing initiatives that support sustainable growth.
